237 related articles for article (PubMed ID: 26971491)
1. Epigenetic field cancerization in gastrointestinal cancers.
Baba Y; Ishimoto T; Kurashige J; Iwatsuki M; Sakamoto Y; Yoshida N; Watanabe M; Baba H
Cancer Lett; 2016 Jun; 375(2):360-366. PubMed ID: 26971491
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathways: involvement of Helicobacter pylori-triggered inflammation in the formation of an epigenetic field defect, and its usefulness as cancer risk and exposure markers.
Ushijima T; Hattori N
Clin Cancer Res; 2012 Feb; 18(4):923-9. PubMed ID: 22205689
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic field for cancerization.
Ushijima T
J Biochem Mol Biol; 2007 Mar; 40(2):142-50. PubMed ID: 17394762
[TBL] [Abstract][Full Text] [Related]
4. Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer.
Spitzwieser M; Holzweber E; Pfeiler G; Hacker S; Cichna-Markl M
Breast Cancer Res; 2015 Sep; 17(1):125. PubMed ID: 26370119
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of the LINE-1 methylation levels in patients with gastrointestinal cancer.
Baba Y; Murata A; Watanabe M; Baba H
Surg Today; 2014 Oct; 44(10):1807-16. PubMed ID: 24150097
[TBL] [Abstract][Full Text] [Related]
6. Long Interspersed Element-1 Methylation Level as a Prognostic Biomarker in Gastrointestinal Cancers.
Baba Y; Yagi T; Sawayama H; Hiyoshi Y; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Baba H
Digestion; 2018; 97(1):26-30. PubMed ID: 29393154
[TBL] [Abstract][Full Text] [Related]
7. [Epigenetic Alterations in Gastrointestinal Cancers: Diagnostic and Therapeutic Applications].
Ushijima T; Maeda M; Kawachi A
Gan To Kagaku Ryoho; 2018 Jan; 45(1):1-7. PubMed ID: 29362296
[TBL] [Abstract][Full Text] [Related]
8. Frequent involvement of chromatin remodeler alterations in gastric field cancerization.
Takeshima H; Niwa T; Takahashi T; Wakabayashi M; Yamashita S; Ando T; Inagawa Y; Taniguchi H; Katai H; Sugiyama T; Kiyono T; Ushijima T
Cancer Lett; 2015 Feb; 357(1):328-338. PubMed ID: 25462860
[TBL] [Abstract][Full Text] [Related]
9. Alteration in DNA methylation patterns: Epigenetic signatures in gastrointestinal cancers.
Heydari Z; Moeinvaziri F; Mirazimi SMA; Dashti F; Smirnova O; Shpichka A; Mirzaei H; Timashev P; Vosough M
Eur J Pharmacol; 2024 Jun; 973():176563. PubMed ID: 38593929
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic biomarkers in gastrointestinal cancers: The current state and clinical perspectives.
Vedeld HM; Goel A; Lind GE
Semin Cancer Biol; 2018 Aug; 51():36-49. PubMed ID: 29253542
[TBL] [Abstract][Full Text] [Related]
11. Aberrant epigenetic patterns in the etiology of gastrointestinal cancers.
Karpiński P; Sasiadek MM; Blin N
J Appl Genet; 2008; 49(1):1-10. PubMed ID: 18263964
[TBL] [Abstract][Full Text] [Related]
12. The bidirectional interplay between ncRNAs and methylation modifications in gastrointestinal tumors.
Kong M; Yu X; Guo W; Guo R
Int J Biol Sci; 2023; 19(15):4834-4848. PubMed ID: 37781524
[TBL] [Abstract][Full Text] [Related]
13. CpG island methylation in precursors of gastrointestinal malignancies.
Chan AO; Rashid A
Curr Mol Med; 2006 Jun; 6(4):401-8. PubMed ID: 16900663
[TBL] [Abstract][Full Text] [Related]
14. Induction of epigenetic alterations by chronic inflammation and its significance on carcinogenesis.
Niwa T; Ushijima T
Adv Genet; 2010; 71():41-56. PubMed ID: 20933125
[TBL] [Abstract][Full Text] [Related]
15. Revisit of field cancerization in squamous cell carcinoma of upper aerodigestive tract: better risk assessment with epigenetic markers.
Lee YC; Wang HP; Wang CP; Ko JY; Lee JM; Chiu HM; Lin JT; Yamashita S; Oka D; Watanabe N; Matsuda Y; Ushijima T; Wu MS
Cancer Prev Res (Phila); 2011 Dec; 4(12):1982-92. PubMed ID: 21952583
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic pathogenesis of human papillomavirus in upper aerodigestive tract cancers.
Talukdar FR; Ghosh SK; Laskar RS; Kannan R; Choudhury B; Bhowmik A
Mol Carcinog; 2015 Nov; 54(11):1387-96. PubMed ID: 25213493
[TBL] [Abstract][Full Text] [Related]
17. The presence of aberrant DNA methylation in noncancerous esophageal mucosae in association with smoking history: a target for risk diagnosis and prevention of esophageal cancers.
Oka D; Yamashita S; Tomioka T; Nakanishi Y; Kato H; Kaminishi M; Ushijima T
Cancer; 2009 Aug; 115(15):3412-26. PubMed ID: 19472401
[TBL] [Abstract][Full Text] [Related]
18. Epigenomic biomarkers for prognostication and diagnosis of gastrointestinal cancers.
Wong CC; Li W; Chan B; Yu J
Semin Cancer Biol; 2019 Apr; 55():90-105. PubMed ID: 29665409
[TBL] [Abstract][Full Text] [Related]
19. Aberrant Epigenetic Modifications of LPHN2 Function as a Potential Cisplatin-Specific Biomarker for Human Gastrointestinal Cancer.
Jeon MS; Song SH; Yun J; Kang JY; Kim HP; Han SW; Kim TY
Cancer Res Treat; 2016 Apr; 48(2):676-86. PubMed ID: 26511811
[TBL] [Abstract][Full Text] [Related]
20. Methylation modification in gastric cancer and approaches to targeted epigenetic therapy (Review).
Zeng XQ; Wang J; Chen SY
Int J Oncol; 2017 Jun; 50(6):1921-1933. PubMed ID: 28498404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
